Molika Ashford

Results from a homologous recombination deficiency assay concordance study led by Friends of Cancer Research were presented at the AMP annual meeting.

At the AMP annual meeting last week, two lab directors shared their experiences and discussed the assay's pros and cons in a company-sponsored workshop. 

The firm cited new study results confirming that an assay analyzing circulating tumor cells isolated by its Parsortix platform can discriminate malignant pelvic masses.

The Swiss company is developing a ctDNA sequencing assay and interpretation software it believes can address hurdles that limit adoption by more hospital labs.

New data suggests that immunotherapy treatment informed by a multi-factorial consideration of tumor features can effectively identify patients most likely to respond.

Ambitions and timelines diverge, but innovators of expanded panels see broad testing as valuable to current patients and future precision oncology innovation.

Hoping to avoid past pitfalls, industry, research, and clinical sectors pledge to work together to expedite circulating tumor DNA as an early endpoint in clinical trials.

Investigators reported that most patients who developed recurrence in their small NSCLC cohort showed a positive ctDNA result by 18 months post-surgery.

With recent response data galvanizing oncologists to expand access to anti-HER2 treatment, digital pathology firm Paige is ramping up efforts to create a companion test.

Investigators shared results of a study this week in which ctDNA residual disease testing gave advance notice of late recurrences in surgically resected HR+ HER2- patients.